Login

Company Executives

$ Management Team

Dr. J. Mel Sorensen

Chairman of the Board

President

Chief Executive Officer

Age 68
Compensation $633.3K USD
Sex Male

Mr. Joel Sussman

Chief Accounting Officer

Treasurer

Secretary

Age 76
Compensation $349.4K USD
Sex Male
Directors
5
serving now
Independent
3 of 3
stated in the proxy; 2 not stated
Average tenure
6.4 years
from year joined
CEO also chairs the board
Yes
J. Mel Sorensen, M.D.
Director Age On board Independent Committees Other public boards 2025 pay Source
J. Mel Sorensen, M.D.
69 2012
14 years
Not stated None stated None stated Paid as CEO
Nancy Chang, Ph.D.
76 2024
2 years
Independent None stated Immix Biopharma, W&T Offshore $38,297
Michael Friedman
48 2024
2 years
Not stated None stated None stated $38,297
Lawrence Alleva
76 2019
7 years
Independent
Audit · Chair Compensation Nominating and Corporate Governance · Chair
Bright Horizons Family Solutions, Inc., Adaptimmune Therapeutics PLC $64,649
Kevin Lokay
69 2019
7 years
Independent
Audit Compensation · Chair Nominating and Corporate Governance
None stated $58,149

Each director opens the passage of the proxy that names them. "Not stated" means the proxy does not say; it never means "no". Pay is the proxy's Director Compensation table; the CEO is paid as an executive.

IntellectMap Corporation
The chief executive officer of IntellectMap is the brother of J. Mel Sorensen, M.D., our Chief Executive Officer and a member of our Board.
$0.2 million
years ended December 31, 2025 and 2024

IntellectMap Corporation provides advisory services to the Company on cybersecurity issues; fees incurred in each year.

Directors and executive officers
Amount not stated

Indemnification agreements requiring the Company to indemnify each director and executive officer to the fullest extent permitted by Delaware law.

Nancy Chang
Now a member of the Board
Amount not stated

Received Series B Preferred Stock in exchange for Nova common stock in the Nova acquisition.

With Nova Pharmaceuticals, Inc. Open in proxy
Michael Friedman
Now a member of the Board
Amount not stated

Received Series B Preferred Stock in exchange for Nova common stock in the Nova acquisition.

With Nova Pharmaceuticals, Inc. Open in proxy
Nancy Chang
$ 500,000

Purchased 7,644,932 shares of common stock in the December 2024 private placement.

Affiliates of Ikarian Capital, LLC
Entities that became related parties as a result of the Private Placement
$ 2,000,000

Purchased 7,538,691 shares of common stock and 23,041,040 pre-funded warrants in the Private Placement.

Michael Friedman
Mr. Friedman, a member of the Board
$10,000 per month
year ended December 31, 2025

Independent Contractor Agreement to provide corporate and business development services, paid $10,000 per month.

With Company Open in proxy
Joel Sussman
Chief Accounting Officer, Treasurer, and Secretary
Up to $250,000

Letter agreement providing retention-based cash bonus payments, up to an aggregate amount, tied to timely completion of reporting obligations.

With Company Open in proxy
J. Mel Sorensen, M.D.
Chief Executive Officer
Amount not stated

In-the-money options to be modified into options to receive Parent common stock in connection with the Obsidian Merger.

With Parent Open in proxy
Joel Sussman
Chief Accounting Officer, Treasurer, and Secretary
Amount not stated

In-the-money options to be modified into options to receive Parent common stock in connection with the Obsidian Merger.

With Parent Open in proxy
Michael Friedman
Member of the Board
Amount not stated

Proposed to serve as an advisor under the CVR Agreement; no economic terms discussed and no formal agreement reached.

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support